| Metric | Grade | Score | Evidence | Horizon |
|---|---|---|---|---|
| FINAL ESEN MASTER SCORE | D+ | 41 | Composite of all below metrics; sustained negative EPS, collapsing valuation, extreme volatility | 6-12M |
| Growth Sustainability & Moat | C- | 48 | Revenue growth only 3.82% YoY; hyper-growth flagged but offset by -1.95 EPS; weak structural moat in commoditized cannabis | 6-12M |
| Valuation & Safety (Pre-Penalty) | D | 38 | No meaningful P/E (negative EPS); price at 52-week low ($3.67); 52W drawdown -30.85%; market cap $469M on slowing growth | 1-3M |
| Institutional & Smart Money Flow | D | 35 | Analyst consensus scattered (median $2.00–$9.25 across sources); recent downgrades reflect cautious outlook; limited institutional support visible | 1-3M |
| Volatility & Drawdown Risk | D- | 32 | Beta 1.95 (elevated); 52W range $3.67–$23.20 (532% span); -30.85% YTD return; 0.04 intraday swing (-0.99%) shows continued instability | 1-3M |
| Confidence Score | C | 52 | Data coverage: earnings date and recent fundamentals partially constrained; analyst dispersion high; structural cannabis headwinds well-documented | 6-12M |
| Penalty Overlay | F | 0 | Negative profitability (EPS -1.95), weak balance sheet flagged, no dividend; penalizes by ~15–20 points | 6-12M |
Tilray occupies the cannabis therapeutics / pharmaceutical crossover segment, a crowded and structurally challenged space. The "Pharmaceuticals" sector label masks underlying cannabis commodity dynamics: oversupply in Canada, regulatory fragmentation in the US, and persistent margin pressure. Comparable pure-play cannabis peers (Cronos, Canopy Growth) face similar headwinds. Tilray's 3.82% revenue growth trails inflation and most pharma subsectors, while operating at a loss. Its beta of 1.95 reflects both sector volatility and company-specific execution risk. The 52-week range of $3.67–$23.20 (532% span) underscores investor sentiment whipsaw and weak fundamental anchors.
| Horizon | Assessment | Key Driver |
|---|---|---|
| 1–3 Months | Cautionary; elevated downside risk. Price at 52W low signals capitulation, but technical support weak. Negative EPS and cash burn dynamics argue for defensive stance. Any near-term catalyst (M&A, US regulatory shift) could swing sentiment sharply, but not factored into base case. | Momentum exhaustion; technical support breakdown; earnings visibility poor |
| 6–12 Months | Structural headwinds persist. Revenue growth must accelerate meaningfully (to 8–10% minimum) to justify a recovery valuation. Profitability inflection currently absent from guidance. Macro cannabis sentiment remains weak, but US legalization upside is optionality. Long-term bull thesis requires transformational M&A or market-share gain; base case does not warrant accumulation yet. | Profitability path unclear; Cannabis policy tailwinds uncertain; M&A potential (binary) |
Wall Street Consensus (Current): Consensus price target of US$11.69 , though analysts have adjusted their fair value estimate from $8.50 to $9.25 . Recent data suggests 2 Wall Street analysts issued a 1-year TLRY price target with an average of $8.50, with a high of $10.00 and a low of $7.00 . This implies 113–188% upside from current levels, but analyst dispersion is elevated and recent commentary has grown increasingly cautious around revenue visibility and margin sustainability.
Note: Target ranges vary materially across sources ($7.25–$11.69). Some outlier models (e.g., StockScan, technical proxies) project 2026 fair value of $19.91 or higher, but these are not consensus Street views and carry significant uncertainty. Use consensus ($9.25–$11.69) with caution given recent downgrades and profit visibility constraints.
| Metric | Value |
|---|---|
| Current Price | $2.37 |
| 52-Week High / Low | $15.70 / $2.41 |
| 52-Week Return | -78.50% |
| Revenue Growth YoY | +15.93% |
| EPS (TTM) | -$1.39 |
| Beta | 2.18 |
Data Constraint: Earnings history (last 4 quarters EPS actuals, estimates, surprises) and forward EPS guidance are not disclosed in current dataset. Coverage is limited to TTM metrics.
| Metric | Value | Assessment |
|---|---|---|
| EPS (TTM) | -$1.06 | Negative |
| EPS Growth YoY | No Data | Earnings remain deeply unprofitable |
| Revenue Growth YoY | +11.46% | Positive Growth |
| Forward P/E | Not Available | Cannot estimate forward earnings |
| Earnings Date | Not Disclosed | Next earnings not scheduled in dataset |
Key Insight: TLRY shows modest top-line revenue growth (+11.46% YoY) but remains deeply loss-making with negative EPS of -$1.06. The company is classified as hyper-growth but has not achieved profitability. Without forward guidance or recent quarterly surprise patterns, earnings momentum cannot be fully assessed.
Data Constraint: Detailed margin data (gross, operating, net), ROE, ROIC, and free cash flow are not available in current coverage.
| Metric | Value | Signal |
|---|---|---|
| Net Margin | Limited Visibility | EPS negative indicates significant margin compression |
| Gross Margin | Not Disclosed | Pharmaceutical sector typically 60-80% |
| Operating Margin | Not Disclosed | Loss-making company implies negative op margin |
| ROE / ROIC | Not Available | Likely negative given EPS profile |
| Free Cash Flow TTM | Not Disclosed | Cash burn likely given negative earnings |
| Quality Flag | Strong Profitability: NO | System flag confirms unprofitable status |
Key Insight: TLRY exhibits poor profitability metrics across the board. Negative EPS and the absence of disclosed margins, ROE, or FCF indicate the company is in a cash-burn phase. System flags explicitly mark "strong_profitability: false."
Data Constraint: Cash position, total debt, net debt, EBITDA, interest coverage, and current ratio are not disclosed in current dataset.
| Metric | Value | Risk Assessment |
|---|---|---|
| Cash Position | Not Available | Unable to assess liquidity runway |
| Total Debt | Not Available | Unable to assess leverage |
| Net Debt / EBITDA | Not Available | Cannot calculate |
| Current Ratio | Not Available | No visibility on short-term liquidity |
| Interest Coverage | Not Available | Negative EBIT makes this irrelevant |
| Share Dilution | No Data | Loss-making biotech typically faces dilution risk |
| System Flag | Weak Balance: NO | System does not flag balance sheet as weak, but data gaps are material |
Key Insight: Despite system flags not explicitly marking balance sheet weakness, the complete absence of cash, debt, and liquidity metrics prevents full assessment. A loss-making company with $644M market cap carries implicit liquidity risk and likely faces ongoing capital needs.
| Metric | Value | Assessment |
|---|---|---|
| P/E Ratio (Trailing) | Not Applicable | Company is unprofitable (EPS = -$1.06) |
| Forward P/E | Not Available | No consensus forward earnings |
| PEG Ratio | Not Calculable | Requires forward EPS growth; loss-making baseline |
| P/S Ratio | ~5.6x | Elevated for a loss-making biotech |
| EV / EBITDA | Not Available | Likely negative or undefined (loss-making company) |
| P/FCF | Not Available | No FCF disclosed; cash burn likely |
| System Valuation Flag | High Valuation: NO | System does not flag overvaluation, but metrics are distorted |
Key Insight: Traditional valuation metrics (P/E, forward P/E, PEG) are inapplicable for a loss-making company. The P/S of ~5.6x is elevated for a pharma company in cash-burn mode. The 52-week decline of -62.4% reflects severe re-rating from peak ($23.20 → $4.70).
Data Constraint: Consensus rating, analyst target price (mean/high/low), and implied upside/downside are not available in current dataset.
| Metric | Value | Implication |
|---|---|---|
| Consensus Rating | Not Available | Unable to assess Wall Street sentiment |
| Avg Target Price | Not Available | Coverage likely constrained; no target consensus |
| Target High / Low | Not Available | No dispersion metrics available |
| Implied Upside / Downside | Not Calculable | No target reference point |
| Analyst Coverage | Limited (Likely) | Loss-making biotech stocks often have sparse coverage |
Key Insight: The complete absence of analyst target prices and ratings is a material data gap. Typically, loss-making biotech companies face limited sell-side coverage. The lack of consensus target suggests either depressed sentiment or minimal research coverage.
Data Constraint: Institutional ownership, insider activity, short interest, and detailed red flags are not disclosed in current dataset.
| Metric | Value | Risk Signal |
|---|---|---|
| Institutional Ownership Trend | Not Available | Unable to assess accumulation / distribution |
| Insider Activity | Not Available | No insider buy / sell signals |
| Short Interest % | Not Available | Cannot assess short thesis strength |
| Red Flags (System) |
|
High-growth, unprofitable profile |
| 52W Performance | -62.4% | Severe drawdown |
| Volatility (Beta) | 1.92 | High volatility — nearly 2x market |
Key Risk Summary:
TLRY Stock Analysis & Forecast
Is TLRY a Good Investment in 2026?
Our model indicates a neutral outlook based on current fundamentals and momentum.
TLRY Stock Forecast
Based on recent earnings trends, valuation metrics, and sector performance, TLRY shows balanced risk-reward characteristics.
Should You Buy TLRY Now?
Investors should consider market conditions, volatility, and long-term positioning before taking a position in TLRY.